Back to our roots, as previous Cambridge alum, the team joined the inaugural Founders at the University of Cambridge programme, sponsored by AstraZeneca.

Through participation in the Nucleate UK Activator Programme, we were awarded $200,000 from Blueyard and invited to speak at the Nucleate Forum (UK) and Nucleate Summit (San Francisco).

Following participation in the UKRI backed Science Creates Accelerator we successfully secured funding for a feasibility study.

Xterna CEO was awarded at an evening celebrating translational contributions of Francis Crick Institute scientists.

Its time for the team to expand! Seeking experts in nucleic acids and immunology. If you’re obsessed with the power of XNA, welcome!

Xterna joins the Bioinnovation Institute Venture Lab programme for 2025/2026. Following a therapeutics focused strand. Watch this space for further updates.

Our team are excited to be nominated for both "New Start-up of the Year" and "Early-Career Entrepreneur of the Year" for our CEO. A big thanks to Cancer Research Horizons for your continued support.

The Golden Ticket programme invited applications from early-stage biotech companies focused on novel drug targets and transformational medicines. After a pitch day, Xterna was announced as the winners of the 5th Golden Ticket competition! This enables us free lab rental and mentorship from Daiichi Sanyko experts.

Team Xterna attended the 2025 Cancer Research Horizons Entrepreneurship awards, and celebrated Jess winning the early career entrepreneur of the year award! Well done to Jess and all the other nominees in this years awards!